AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR
"Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the development, manufacturing, and distribution of therapeutic drugs such as Eylea and Eylea HD (high dose) in the US for the treatment of various retinal disorders including wet Age-Related Macular Degeneration (wAMD)."
Key players in the Age-Related Macular Degeneration (AMD) drugs market include Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland)
The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust CAGR of 10.7%. This growth is driven by rising AMD prevalence linked to lifestyle changes, increased R&D investment leading to more drug approvals, and improved reimbursement policies. The market is particularly expanding in developing countries and is witnessing a shift towards innovative therapies like gene therapy. However, challenges like high treatment costs and the off-label use of drugs such as Avastin hinder market potential. Notably, Eylea remains the leading product, while dry AMD therapies are expected to grow rapidly due to escalating cases among the aging population. North America is projected to be the fastest-growing region, with significant annual AMD case increases. Key players include Regeneron, Bayer, and Novartis, among others, with recent developments indicating a strong focus on new therapeutic solutions.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37446234
Browse in-depth TOC on " Age-related Macular Degeneration (AMD) Drugs Market"
378 - Tables
54 - Figures
336 - Pages
Based on molecules, the global Age-Related Macular Degeneration (AMD) drugs market has been segmented into Ranibizumab, Aflibercept, Faricimab, Pegcetacoplan, and other molecules including conbercept, brolucizumab, avacincaptad pegol, and bevacizumab-gamma among others. In 2023, aflibercept held the largest share of the Age-Related Macular Degeneration (AMD) drugs market by molecule. This large share of the molecule can be attributed to the high adoption of this molecule for the treatment of the wet or neovascular form of AMD. This adoption is due to the high affinity of the molecule for VEGF proteins preventing activation of native VEGF receptors and reducing angiogenesis and vascular permeability. Moreover, the efficacy of the molecule is supported by various research studies comparing the effectiveness of this molecule to other molecules used for AMD treatment. Additionally, the ongoing development of novel drug delivery methods and biosimilars for this molecule further supports the growth of the market of this molecule.
Based on the type of AMD, the global Age-Related Macular Degeneration (AMD) drugs market has been segmented into wet AMD and dry AMD. In 2023, the wet AMD disease segment accounted for the largest share of the AMD market by type of AMD. The large share of wet AMD can be attributed to the rising prevalence of this disease affecting more than 20 million individuals globally. Reports from leading pharmaceutical companies highlight that more than 200,000 cases of wet AMD are reported in the US every year. This increase in wet AMD cases is attributed to the rising geriatric population with the World Health Organization (WHO) estimating a 2x increase in the number of individuals over 60 years of age by 2050. This market is also supported by new entrants targeting patients earlier in the disease cascade, with new drugs such as new entrants targeting patients earlier in the disease cascade with new drugs such as OPT-302 and KSI-301 being developed for the treatment of this disease.
Based on end users, the global age-related macular degeneration (AMD) drugs market has been segmented into hospitals, specialty centers, and long-term care facilities. Hospitals accounted for the largest share of the AMD drugs market by end user in 2023. The large share of this segment is attributed to the rising prevalence of AMD cases and the ability of hospitals to provide advanced healthcare infrastructure and specialized treatment capabilities that aid in the treatment of patients with AMD. Furthermore, hospitals also support research that facilitates the development of better treatment for various diseases including AMD. Hospitals collaborate with pharmaceutical companies to ensure the optimal availability of AMD drugs for patients while providing comprehensive care, including diagnostics, treatment administration, and patient monitoring to enhance treatment outcome for the patients.
The key regional markets for age-related macular degeneration (AMD) drugs market are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2023, North America accounted for the largest share of the market. This can be attributed to the increasing AMD cases in the region with reports from major pharmaceutical companies highlighting the occurrence of more than 200,000 new cases of AMD every year in the US. A rise in obesity, smoking, and poor diet in this region further contributes to the increase in the number of AMD cases. Additionally, an increase in the number of approvals for AMD drugs in the region further supports the market growth. Advanced healthcare infrastructure in these regions, including access to specialists and diagnostic tools, supports early detection and treatment.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37446234
The prominent players in the global Age-Related Macular Degeneration (AMD) market are Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US), Coherus BioSciences (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China) and Sandoz Group AG (Switzerland). The market also includes players, such as Stealth BioTherapeutics Inc. (US), Ocular Therapeutix, Inc. (US), Opthea Limited (Australia), Kodiak Sciences Inc. (US), Innovent (China), Bio-Thera Solution (China), Alvotech (Iceland), Alteogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), Amgen Inc. (US), Ocumension Therapeutics. (China), and Adverum Biotechnologies, Inc. (US), that have drug candidates in phase 3 clinical trials.
Regeneron Pharmaceuticals Inc. (US):
Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the development, manufacturing, and distribution of therapeutic drugs such as Eylea and Eylea HD (high dose) in the US for the treatment of various retinal disorders including wet Age-Related Macular Degeneration (wAMD). Eylea is one of the most adopted therapeutic drugs for the treatment of wet AMD across the globe. The company has partnered with major pharmaceutical companies such as Bayer AG to manufacture and distribute the drugs outside the US. Regeneron has operations in over 12 countries across the Asia Pacific, Europe, and North America, and conducts clinical trials in more than 60 countries. In 2023, the company allocated USD 96.2 million to improve Eylea HD, a higher hose of its already successful AMD drug Eylea. This drug allows patients to obtain similar therapeutic results with less number of injections reducing the treatment burden on the patients. The company has also developed innovative technologies like TRAPS and VelociSuite, which are used for the development of bispecific antibodies, essential for the development of next-generation ophthalmic drugs.
F. Hoffmann-La Roche Ltd (Switzerland):
Roche is a major pharmaceutical company that offers three FDA-approved drugs for the treatment of wet AMD among other retinal diseases: Lucentis, Vabysmo, and Susvimo, the company also provides Avastin (Bevacizumab) which is widely used as an off-label drug for the treatment of wet AMD owing to its affordability. In 2023, the company invested approximately 22% (USD 14.7 billion) of its annual revenue in R&D for the development of new drugs and exploring advanced research methods, including computational biology. The company has received marketing approvals for its AMD drugs in many countries, with recent expansions into markets like India. Roche's Genentech Ophthalmology Co-pay Program helps cover drug and administration costs making treatments more affordable. The company has operations in over 95 countries and offers a wide range of therapeutic products for a variety of diseases and disorders.
Novartis AG (Switzerland):
Novartis AG is a biotechnology company that focuses on the development and distribution of innovative medicines across key therapeutic areas, including cardiovascular, renal, metabolic, immunology, neuroscience, ophthalmology, and oncology. In 2023, Novartis became a pure-play innovative medicines company by spinning off its Sandoz generic and biosimilar business unit. The company strongly focuses on ophthalmology, and markets FDA-approved drugs like Lucentis and Beovu (brolucizumab) for treating wet Age-Related Macular Degeneration (AMD) across the globe. Novartis is also conducting phase 3 clinical trials for Beovu to expand its use for diabetic retinopathy, highlighting the company's focus on innovation and expanding treatment options. The company operates in over 130 countries and uses contract structures such as pay-over-time and outcome-based agreements to make its products more affordable and accessible to patients.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 hours ago
- Globe and Mail
Canadian chip company Untether AI winding down operations
Promising Canadian chip startup Untether AI Corp. is winding down after failing to raise money earlier this year, and its engineering employees will be transferred to American company Advanced Micro Devices AMD-T. The arrangement is known as an 'acquihire,' in which one company strikes a deal with another to gain access to talent instead of products or services. Toronto-based Untether designed computer chips for artificial intelligence applications such as autonomous vehicles, robots and drones, and said its products were far more energy efficient than others on the market. But the company pivoted too late to the hardware market for powering generative AI applications, such as OpenAI's ChatGPT, according to two sources familiar with the matter, and struggled to compete against the dominance of Nvidia Corp. NVDA-T in the chip market. Economic uncertainty owing to U.S. President Donald Trump's tariff agenda contributed to difficulties raising new funds from investors this year, one of the sources said. The Globe and Mail is not identifying the sources because they are not authorized to discuss the matter. Untether said in a statement on its website Thursday that it had entered into a 'strategic agreement' with chipmaker AMD, which is based in California. 'While today marks the end of Untether AI's journey, we are proud of the pioneering research that underpinned our work,' the statement read. The company added it will no longer supply or support its hardware and software products. AMD said in a statement to trade publication CRN that it is acquiring 'a talented team of AI hardware and software engineers' from Untether. One source said the value of the deal would likely be less than US$100-million depending on how many employees agree to join AMD. The source added that Meta Platforms Inc., which is working on custom chips for AI applications, was also in talks with Untether. It is not clear what will happen to Untether's intellectual property, which is not part of the transaction, but the source said it could be sold separately. Neither Untether nor AMD immediately replied to a request for comment. From 2024: Toronto's Untether straps in for growth selling AI chips - but can it avoid getting crushed by Nvidia? Chris Walker, Untether's chief executive, left the company in May, according to his LinkedIn profile. He did not reply to The Globe and Mail. Untether was founded in 2018 and received funding from Intel Capital, Radical Ventures, GM Ventures and Canada Pension Plan Investment Board. The company has raised around $150-million. That means given the potential value of the deal, investors are likely not recouping the total amount they invested. However, losses will depend on when investors first put money into Untether. The company's products were built on the research of co-founder and former University of Toronto professor Martin Snelgrove, who pioneered a different computer chip architecture. The dominant approach to chip-making has followed a design laid out by mathematician and physicist John von Neumann in 1945, but that design wastes a lot of energy shuttling data around. Untether cut the distance data must travel by placing memory and processing units side-by-side on the hardware. Untether pursued the self-driving vehicle market and other systems that use a form of AI know as computer vision, which involves detecting and interpreting objects in videos and images. But the AI world changed with the release of ChatGPT in late 2022, as companies became obsessed with generative AI and chatbots. Nvidia became the most valuable publicly traded company in the world as large tech firms scrambled to purchase chips to install inside data centres for training AI models. Untether aimed to compete with Nvidia in the much larger market for powering AI inference, the term for using an AI model after it is built, such as asking a question of ChatGPT. Independent tests gave Untether's products high marks. MLCommons, an industry and academic consortium that benchmarks AI systems, found last year that one of Untether's chips was six times more energy efficient than competing products, and with lower latency, in one testing category. But Untether's push into the market for chips housed in data centres for generative AI may have come too late, especially given Nvidia's scale and reputation. The California-based company is worth close to US$3.5-trillion.
Globe and Mail
14 hours ago
- Globe and Mail
Should You Invest $1,000 in Taiwan Semiconductor Stock Today?
During the month of May, stocks started exhibiting some much-needed resilience. The S&P 500 and Nasdaq Composite indexes rose by 5% and 8%, respectively. After bearing the brunt of precipitous sell-offs early this year, semiconductor stocks have started to stage a comeback. Last month, shares of Nvidia and Broadcom climbed by more than 20%, while Advanced Micro Devices surged by roughly 15%. Lagging behind the usual suspects, however, was Taiwan Semiconductor Manufacturing (NYSE: TSM). While the stock's 12% gains beat the broader market, they still trail the chip industry's leading names. Below, I'll delve into why Taiwan Semi looks like a great buy right now. From there, I'll illustrate how a $1,000 investment could wind up being a multibagger for patient, disciplined investors. A hidden gem in a sea of semiconductor stocks Nvidia and AMD design chipsets known as graphics processing units (GPU). GPUs have the capability to run sophisticated calculations at fast speeds, which gives them an edge over traditional compute processes when it comes to developing generative AI applications. Cloud hyperscalers such as Microsoft, Alphabet, and Amazon, as well as big tech giants Meta Platforms and Oracle, have been buying GPUs in droves over the last few years in an effort to build out data centers and infrastructure services. While the robust demand for chips directly benefits Nvidia and AMD, Taiwan Semi has been an indirect beneficiary of these tailwinds. The reason? Because Taiwan Semi specializes in foundry services that actually manufacture the chip designs from Nvidia, AMD, and many others. In other words, the largest data center businesses in the world rely heavily on Taiwan Semi's fabrication business. Taiwan Semi is positioned for monster growth In the chart below, I've illustrated Taiwan Semi's revenue, gross profit, and net income over the last three years. As the slopes of the lines indicate, TSMC's sales and profitability profile are both steepening. TSM Revenue (TTM) data by YCharts To me, this signals two things. First, demand for chips is on the rise -- hence the revenue line is rising. However, the more lucrative trend is that gross margin and net income are accelerating in parallel with sales. This suggests that Taiwan Semi has achieved a fair degree of pricing power relative to competitors such as Intel. Considering AI infrastructure spend is expected to eclipse multiple trillions over the next five years, I don't see Taiwan Semi's growth prospects decelerating anytime soon. Should you invest $1,000 in TSMC stock? It's worth noting that technology investors Cathie Wood and Stanley Druckenmiller each recently added Taiwan Semi stock to their firms' respective portfolios. While blindly following institutional capital flows isn't necessarily a prudent strategy, I do think TSMC's long-term prospects earn some more credibility thanks to the recent buys by such prominent investors. In the chart below, I've illustrated how a $1,000 investment in Taiwan Semi stock 10 years ago is now worth approximately $8,500. Achieving almost a tenfold return in 10 years is impressive -- even for a growth stock. TSM data by YCharts There are a couple of important ideas to take away from the chart above. First, the trends clearly show that like many of its peers, TSMC stock has kicked into a new gear over the last couple of years thanks to a bullish AI narrative. Hence, the share price gains following the sell-off in 2022 appear overly pronounced. Here's the thing, though: Had you invested $1,000 in Taiwan Semi stock on Nov. 30, 2022 (the day ChatGPT was commercially launched), you would have doubled your money. This underscores the idea that holding on to a stock for long-term periods (i.e. 10 years or more) can lead to outsized gains compared to shorter-term, volatile periods. I think now is a great time to invest $1,000 in Taiwan Semi stock. The company's future growth prospects are arguably far more robust than they were 10 years ago, making now an interesting time to begin accumulating shares for a long-run position. Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Meta Platforms, Microsoft, Nvidia, Oracle, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Japan Forward
a day ago
- Japan Forward
Japan Trials First Full-Flat Sleeper Bus
Japan's first trial run of a highway bus with full-flat seats is now underway, aiming to challenge the common view of night buses as cramped and tiring. The seats were jointly developed by Kochi-based operator Kochi Ekimae Kanko, a local model-making company, and a machinery manufacturer. Made entirely in Kochi, they meet the full-flat seating guidelines introduced by the Ministry of Land, Infrastructure, Transport and Tourism in November 2024. Since March, Kochi Ekimae Kanko has been operating a weekly round trip between Tokyo and Kochi on a trial basis, receiving positive feedback. With hotel prices climbing due to increasing inbound tourism, the service also aims to appeal to cost-conscious travelers. The full-flat seats are called Sommeil Profond, French for "deep sleep." Two rows of seats, front and back, convert into bunk-style beds, creating a private space similar to a capsule hotel. A large coach was remodeled to accommodate 24 seats across 12 bunk-style units arranged in three rows. The trial service began on March 11, running once a week between Tokyo and Kochi or Tokushima. The longest stretch of the trip takes about 13.5 hours one way. Passengers can stay fully reclined the entire time. Each seat is enclosed by curtains for privacy and comes with amenities like a blanket and pillow, offering a semi-private experience. The regular fare is expected to be around ¥13,000 JPY (about $90 USD), though the trial price has been set between ¥7,000 and ¥7,500. On the morning of May 21, the trial bus arrived at Kochi Station fully booked with passengers traveling for sightseeing or business. Yukari Ikezawa, a 37-year-old office worker from Kochi who took the round trip, said, "The vibrations bothered me a little, but on the way back, I was so tired I slept soundly. I felt much less fatigued compared to a regular bus." A company representative added, "These seats significantly reduce fatigue compared to standard ones. And since passengers can sleep while traveling, it also helps cut down on hotel expenses." Seats arranged to make full-flat "beds." (Courtesy of Kochi Ekimae Kanko) About 30 years ago, Kochi Ekimae Kanko's Chairman Kuninori Umehara saw sleeper buses during a visit to China. The company considered bringing the concept to Japan but had to put the idea on hold due to the lack of a legal framework at the time. Around 10 years ago, the company confirmed that there were no regulations on seat reclining angles. This opened the door to the idea of converting traditional seat designs into fully flat beds, and development began. Creating bus seats involves specialized knowledge and technical skills. To take on the challenge, the company partnered with local model maker Thermal Kobo and industrial machinery manufacturer Kakiuchi. Together, they repeatedly refined prototypes that could fold flat, maximize cabin space, and meet safety standards. They also consulted closely with Japan's transport ministry. It was determined that as long as the seats could return to an upright position, the bus would pass inspection under the Road Transport Vehicle Act. At the time, international safety standards for vehicle seating were based on a 25-degree seatback angle, and there was no established method to assess the safety of fully flat seats. However, as global discussions around safe seating in various postures began to grow, the ministry anticipated rising demand and introduced formal guidelines in November 2024. The guidelines require the following: A fall-prevention plate that can withstand 900 kilograms of force Two-point seatbelts Padding and safety features to prevent falls from the head and sides Clear evacuation routes and secure luggage storage Kochi Ekimae Kanko refined its design to meet these standards and successfully turned the concept into reality. Since the trial began, buses equipped with Sommeil Profond seats have been nearly full. Surveys show that about 80% of users gave the ride high marks, especially for reduced fatigue and improved sleep quality. The most common complaint, however, was the narrow bed size. In bed mode, each seat measures 180 cm (5.9 ft) in length, 48 cm in width, and 51 to 73 cm in height, depending on the seat. Some larger passengers reportedly have to curl up to fit. "There's definitely room for improvement," said a company representative. "But seat size is closely tied to pricing, so we have to be careful when considering any changes to the design." Wider seats would improve comfort but reduce the total number of seats. Since operating costs per bus trip — such as fuel — are mostly fixed, fewer seats would lead to higher fares. For reference, a standard 28-seat, three-row bus charges about ¥10,000 on the Kochi–Tokyo route. The full-flat model accommodates 24 seats, allowing fares in the ¥13,000–¥14,000 range. Passengers have also requested more storage space and power outlets. The company is reviewing these suggestions and plans to expand service this fall with two buses offering four round trips per week. Looking ahead, Kochi Ekimae Kanko aims to market the Sommeil Profond model nationwide. Talks are already underway with bus operators in Tohoku and Kyushu, and interest has been strong. A representative said, "Eventually, we believe half of all overnight highway buses could adopt full-flat seating. By switching between upright and flat modes, these buses could even serve as a new option for inbound tourism. We want to keep improving and expand this model across Japan." ( Read the article in Japanese . ) Author: Koji Maekawa, The Sankei Shimbun
